As the pre-election momentum builds around "MediCare For All", healthcare stocks have become quite jittery. Drug stocks, and in particular the biotech companies, have seen selling pressure over the last few weeks with the major concern being that the...
Tailwinds' Take: this is a very positive step for Anixa as it insures that they have rights to this treatment as a platform for multiple solid tumor cancers. If this CAR-T is successful, it will potentially be the first...
Tailwinds' Take: I believe investors don't quite get the lack of support for the PSA in the medical community. Cchek, if and when approved, has the potential to be a very big product for Anixa. With increasing support, the...
SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study on prostate cancer detection, utilizing...
On May 15th, Dr. Amit Kumar will be on a panel discussing cancer therapies for solid tumors. This panel is at a conference hosted by the New York Academy of Sciences. Here is the official agenda item, from their...
Tailwinds' Take: two keys to this press release. First, this should provide a steady stream of samples, keeping the timeline intact for developing the diagnostic with ResearchDX and getting it to market in Q3. Secondly, more Key Opinion Leader's...
Tailwinds' Take: another oral presentation, at a key conference no less, is going to help Cchek gain recognition right before its launch. Interestingly, data on other cancers than prostate and breast will be presented. This is a very positive...
Tailwinds' Take: this is positive for a couple reasons. Oral presentations are not handed out willy-nilly...it shows that the medical community is catching on to Anixa and excited about what they're doing. Also, since it's on benign data, which...
This morning, Anixa announced that they have achieved one of their key milestones for 2019, namely that of partnering with an independent clinical laboratory to develop and launch a prostate cancer diagnostic. This is a significant development for the...
Tailwinds' Take: Anixa is executing to their plan. Having a diagnostic in the market by Q3 should be eye-opening for institutional investors who have ignored ANIX to date. We continue to believe this could be our best performing stock...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.